But, with Applied Genetic Technologies Corporation, can lightning strike a third time?
The group looks like the gene therapy contender to beat, but that is not saying much.
In 2020 76 biotech floats raised a combined $12.7bn. Foghorn is not the first to show that much of the faith was misplaced.
Spac backtrack confirms that the gene therapy bubble has burst
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.